Products
Online Inquiry
KML29
Cat. No.:
OB0225WX-1870
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
KML29 is a highly selective monoacylglycerol lipase (MAGL) inhibitor with IC50 values of 5.9 nM, 15 nM, and 43 nM for human, mouse, and rat isoforms, respectively, showing no activity against FAAH.
Synonym:
1380424-42-9; KML-29; 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]piperidine-1-carboxylate; 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(benzo[d][1,3]dioxol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate; KML 29; 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(1,3-benzodioxol-5-yl)-hydroxymethyl)piperidine-1-carboxylate; 1,1,1,3,3,3-Hexafluoro-2-propanyl 4-[bis(1,3-benzodioxol-5-yl)(hydroxy)methyl]-1-piperidinecarboxylate
CAS No.:
1380424-42-9
Compound CID:
71656212
Formula:
C24H21F6NO7
Formula Weight:
549.42
Specification
Targets&IC50:
MAGL (rat): 43 nM; MAGL (human): 5.9 nM; MAGL (mouse): 15 nM; AEA: >50 μM; 2-AG: 2.5 nM
Relative Density:
1.511 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
KML29 is applied in neuropharmacology as a highly selective and potent MAGL inhibitor to study the reduction of pro-inflammatory eicosanoid production and its efficacy in chronic pain models.
Library Information
Target:
Lipase
Receptor:
MAGL
Pathways:
Metabolism
Plate Number:
AOCL-24
Plate Location:
h11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 91 mM
